Reports

Drug name	NICE TAs	Comments
Sunitinib capsules	TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA) TA169 - Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma TA179 - Sunitinib for the treatment of gastrointestinal stromal tumours TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	Hospital use only
Tacrolimus 0.03% ointment (30g)	TA82 - Tacrolimus and pimecrolimus for atopic eczema
Tacrolimus 0.1% ointment (30g)	TA82 - Tacrolimus and pimecrolimus for atopic eczema
Tacrolimus capsules (Prograf)	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant
Tacrolimus capsules (Prograf)#amber	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015
Tacrolimus prolonged release capsules (Advagraf)	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant
Tacrolimus prolonged release capsules (Advagraf)#amber	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015
Tadalafil 10mg	TA273 - Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)	High relative cost. In line with SLS criteria. Four tab per month - on demand. Non-formulary for LUTS in BPS.
Teduglutide (Revestive®)	TA804: Teduglutide for treating short bowel syndrome
Temozolomide capsules	TA121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma TA23 - Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports